Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Oral Anticancer Drugs”

36 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 36 results

Early research (Phase 1)Study completedNCT01900028
What this trial is testing

To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours

Who this might be right for
Solid Tumours
AstraZeneca 85
Early research (Phase 1)Study completedNCT01894256
What this trial is testing

Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function

Who this might be right for
Solid Tumours
AstraZeneca 56
Early research (Phase 1)Study completedNCT02161770
What this trial is testing

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Who this might be right for
Solid Tumours
AstraZeneca 30
Not applicableLooking for participantsNCT06317389
What this trial is testing

PACOME (PAtient Cancer Oral MEdication) Cohort of Patients Treated With Oral Anticancer Drugs Benefiting From Oncoral Multidisciplinary Monitoring in Real Life: Predictive Factors and Safety of Treatments

Who this might be right for
CancerOncologyOncoral Program
Hospices Civils de Lyon 3,000
Not applicableUnknownNCT06566560
What this trial is testing

The ROAD 2.0 to Sustainable Medication Use: Redispensing Unused Oral Anticancer Drugs

Who this might be right for
CancerOncologyPharmacy+1 more
Radboud University Medical Center 2,500
Early research (Phase 1)Study completedNCT01929603
What this trial is testing

Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours

Who this might be right for
Solid Tumours
AstraZeneca 32
Not applicableStudy completedNCT03952312
What this trial is testing

Oncotool for Cancer Medications

Who this might be right for
CancerCancer, Treatment-RelatedMedication Adherence+2 more
Northwestern University 83
Not applicableUnknownNCT04142463
What this trial is testing

Collaborative Network to Take Responsibility for Oral Anticancer Therapy 2

Who this might be right for
Oncologic Disorders
Ilyse Kenis 500
Not applicableUnknownNCT03296150
What this trial is testing

ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE

Who this might be right for
CancerOral Anticancer Drugs
Hospices Civils de Lyon 139
Early research (Phase 1)Study completedNCT02908750
What this trial is testing

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05548127
What this trial is testing

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Who this might be right for
Breast Cancer
Pfizer 37
Not applicableStudy completedNCT07073807
What this trial is testing

Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy

Who this might be right for
CancerNeoplasms
University of California, Irvine 35
Early research (Phase 1)Study completedNCT02157883
What this trial is testing

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 39
Not applicableStudy completedNCT02833246
What this trial is testing

Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications

Who this might be right for
SarcomaLungSolid Tumor Gastrointestinal
Memorial Sloan Kettering Cancer Center 28
Not applicableUnknownNCT02733965
What this trial is testing

Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events

Who this might be right for
Oral Anticancer Therapy.
Assistance Publique Hopitaux De Marseille 190
Not applicableUnknownNCT02861209
What this trial is testing

Collaborative Network to Take Responsibility for Oral Anticancer Therapy

Who this might be right for
Breast CancerALLLung Cancer+3 more
KU Leuven 228
Not applicableLooking for participantsNCT03257969
What this trial is testing

Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients with Risk Factors

Who this might be right for
Cancer
Hospices Civils de Lyon 248
Not applicableLooking for participantsNCT06726889
What this trial is testing

Increasing Oral Medication Adherence for Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
European Institute of Oncology 104
Not applicableUnknownNCT04613765
What this trial is testing

A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting

Who this might be right for
AdultsHematological MalignancyOral Antineoplastic Agents
Jules Bordet Institute 113
Not applicableUnknownNCT03660670
What this trial is testing

Medico-economic Evaluation of the ONCORAL Program for Ambulatory Patients Under Oral Anticancer Drugs Versus Usual Care

Who this might be right for
Cancer
Hospices Civils de Lyon 215
Next Page